Status:
NOT_YET_RECRUITING
Surveillance After Resection of Oesophageal aNd Gastric Cancer (SARONG-II) Trial
Lead Sponsor:
University of Dublin, Trinity College
Collaborating Sponsors:
Trinity St. James's Cancer Institute
University of Oxford
Conditions:
Esophageal Cancer
Gastric Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Cancer of the food pipe (oesophagus) and stomach are increasingly common. Currently, most patients with cancer of the oesophagus and stomach are treated with surgery with or without additional chemoth...
Detailed Description
It is an encouraging trend that the overall survival rate for oesophagogastric cancer has doubled over the last 20 years. For patients with locally advanced disease treated with curative intent, 5 yea...
Eligibility Criteria
Inclusion
- A patient will be eligible for inclusion in this study if all of the following criteria apply:
- Has undergone surgical resection for curatively intended treatment of oesophageal or gastric cancer (adenocarcinoma and squamous cell carcinoma) with or without neoadjuvant/adjuvant chemotherapy or radiotherapy or immunotherapy (or in combination).
- Aged 18 years or over
- Willing and able to give informed consent
- A patient with not be eligible for the trial if any of the following apply:
- 1\. Other cancer(s) undergoing treatment or surveillance
Exclusion
Key Trial Info
Start Date :
November 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2029
Estimated Enrollment :
952 Patients enrolled
Trial Details
Trial ID
NCT06115629
Start Date
November 1 2023
End Date
November 1 2029
Last Update
November 3 2023
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Cologne
Cologne, Germany
2
Mercy University Hospital
Cork, Ireland
3
Trinity St. James's Cancer Institute
Dublin, Ireland
4
Galway University Hospital
Galway, Ireland